SAN DIEGO, Oct. 24, 2017 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will report third quarter 2017 results after the Nasdaq market
close on November 1, 2017.
Neurocrine will then host a live conference call and webcast
to discuss its financial results and provide a Company update that
day at 5:00pm Eastern Time
(2:00pm Pacific Time).
Participants can access the live conference call by dialing
866-831-8713 (US) or 203-518-9713 (International) using the
conference ID: NBIX. The call can also be accessed via the webcast
through the Company's website at http://www.neurocrine.com.
If you are unable to attend the webcast and would like further
information on this announcement, please contact the Investor
Relations Department at IR@neurocrine.com. A replay of the
conference call will be available approximately one hour after the
conclusion of the call by dialing 800-839-4013 (US) or 402-220-2982
(International) using the conference ID: NBIX. The call will be
archived for one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a San Diego based
biotechnology company focused on neurologic, psychiatric and
endocrine related disorders. The Company markets
INGREZZA® (valbenazine) capsules in the United
States for the treatment of adults with tardive
dyskinesia. INGREZZA is a novel, selective vesicular
monoamine transporter 2 (VMAT2) inhibitor, and is the first FDA
approved product indicated for the treatment of adults with tardive
dyskinesia. The Company's three late-stage clinical programs
are: elagolix, a gonadotropin-releasing hormone antagonist for
women's health that is partnered with AbbVie Inc.; opicapone,
a novel, once-daily, peripherally-acting, highly-selective
catechol-o-methyltransferase inhibitor under investigation as
adjunct therapy to levodopa in Parkinson's patients; and INGREZZA,
a novel, once-daily, selective VMAT2 inhibitor under investigation
for the treatment of Tourette syndrome.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
View original
content:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-third-quarter-2017-results-300542286.html
SOURCE Neurocrine Biosciences, Inc.